Terminated × Lymphoma, B-Cell, Marginal Zone × Rituximab × Clear all Pembrolizumab in MarginalzoneLymphoma A MULTICENTER OPEN LABEL SINGLE-ARM PHASE II STUDY
Phase 2 Terminated
22 enrolled 20 charts
Acalabrutinib in Combination With R-ICE For Relapsed or Refractory Lymphoma
Phase 2 Terminated
2 enrolled 6 charts
Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer
Phase 1 Terminated
17 enrolled
Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL)
Phase 3 Terminated
82 enrolled 11 charts
Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
Phase 2 Terminated
3 enrolled 11 charts
QUILT-3.002: N-803 in Patients With Relapse/Refractory iNHL in Conjunction With Rituximab
Phase 1/2 Terminated
43 enrolled 15 charts
Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer
Phase 2 Terminated
20 enrolled 8 charts
A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma
Phase 1 Terminated
97 enrolled
Carfilzomib With or Without Rituximab in the Treatment of Waldenstrom Macroglobulinemia or Marginal Zone Lymphoma
Phase 2 Terminated
4 enrolled 12 charts
Clofarabine and Rituximab in Treating Patients With Relapsed Non-Hodgkin Lymphoma
Phase 1/2 Terminated
2 enrolled 4 charts
Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation
Phase 2 Terminated
4 enrolled 4 charts
Bridalveil
Phase 3 Terminated
475 enrolled 9 charts
Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Phase 1/2 Terminated
81 enrolled 16 charts
CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Phase 1 Terminated
1 enrolled
Alisertib With and Without Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Phase 2 Terminated
14 enrolled 11 charts
Antithymocyte Globulin, Clofarabine, and Rituximab in Treating Patients After an Unsuccessful Stem Cell Transplant
Phase 2 Terminated
12 enrolled 12 charts
Donor Natural Killer Cell Infusion, Rituximab, Aldesleukin, and Chemotherapy in Treating Patients With Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia
Phase 1/2 Terminated
6 enrolled 10 charts
Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Non-Hodgkin's Lymphoma
Phase 2 Terminated
12 enrolled 7 charts
Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant
Phase 2 Terminated
3 enrolled 10 charts
Rituximab, Combination Chemotherapy, and 90-Yttrium Ibritumomab Tiuxetan for Patients With Stage I or II Non-Hodgkin's Lymphoma
Phase 2 Terminated
62 enrolled 8 charts
Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin Lymphoma
Phase 1 Terminated
5 enrolled
Fenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma
Phase 1/2 Terminated
32 enrolled 7 charts
Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Cancer
Phase 2 Terminated
36 enrolled 16 charts
Radiolabeled Monoclonal Antibody in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Phase 1 Terminated
18 enrolled
Irradiated Donor Lymphocytes and Rituximab in Treating Patients With Relapsed or Refractory Lymphoproliferative Disease
Phase 1 Terminated
2 enrolled
Bortezomib and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
Phase 2 Terminated
46 enrolled